Integration of collagen matrices into the urethra when implanted as onlay graft

Objective: To assess the integration of decellularized heterologous collagen matrices into the urethra, when implanted with no cells or when seeded with autologous smooth muscle cells.Materials and Methods: Eighteen New Zealand rabbits were randomly assigned to two groups: Group I (n = 9) - animals undergoing urethral segment resection with interposition of a patch of heterologous collagen matrix seeded with autologous smooth muscle cells; Group II (n = 9) - animals undergoing resection of a urethral segment with interposition of a decellularized heterologous collagen matrix patch. Two animals from each group were sacrificed on postoperative days seven, fourteen and twenty-eight; three animals from each group were sacrificed at the end of three postoperative months. At the end of the third month one animal from each group underwent urethroscopy for urethral integrity assessment and one animal from each group had its microcirculation image captured by a SDF device (Side-stream Dark Field - Microscan Analysis Software). One animal from each group in each euthanasia period underwent cystourethrography so as the urethra could be viewed at flow time. the matrices integration was assessed through histological examination using hematoxylin and eosin (H&E), Masson trichrome (MT), Picrosirius red and Von Willebrand staining. in a blind study with two pathologists all the slides were studied.Results: the matrices whether seeded or not with autologous muscle cells were able to restore the architecture of the urethra, but were eliminated from the first week on, before incorporation. Microcirculation of the neourethra, at the end of the third month, showed the same characteristics as a normal urethra in both groups of animals.Conclusion: Natural heterologous matrices implanted in the urethra as onlay graft were not incorporated into its walls but were able to fully restore the cell architecture of the organ, regardless of being seeded or not with autologous muscle cells.Universidade Federal de São Paulo, Dept Surg, São Paulo, BrazilUniversidade Federal de São Paulo, Dept Nephrol, São Paulo, BrazilUniversidade Federal de São Paulo, Dept Pathol, São Paulo, BrazilUniversidade Federal de São Paulo, Dept Surg, São Paulo, BrazilUniversidade Federal de São Paulo, Dept Nephrol, São Paulo, BrazilUniversidade Federal de São Paulo, Dept Pathol, São Paulo, BrazilWeb of Scienc

Determinação imunohistoquímica da presença de células mióides em pacientes submetidos à timectomia

OBJETIVO: Detectar e quantificar células mióides em timos de pacientes com miastenia grave, estabelecendo possível correlação entre a quantidade de células mióides com variáveis demográficas e clínico-patológicas. MÉTODO: Foram analisados por meio de método imuno-histoquímico com anticorpo antidesmina (clone D33; marca Dako), timos de 22 pacientes (16 mulheres e seis homens, entre 12 e 61 anos) submetidos à timectomia, entre 1981 e 1995, no Serviço de Cirurgia Torácica do Hospital Heliópolis como parte do tratamento de miastenia grave. RESULTADOS: As maiores médias de células mióides foram encontrados em timos dos pacientes da raça negra (29,4:17,8), do sexo feminino (23,2:13,0) e com faixa etária entre 60 e 80 anos (média de 33,0). Pela classificação clínica da Fundação de Miastenia Grave da América (MGFA), a maior média de células mióides (26,7) encontra-se na classe IIIa, sendo do tipo histológico de hiperplasia verdadeira (média 42,0). As células mióides foram identificadas em 11 timos com hiperplasia linfóide, três hiperplasias verdadeiras e em quatro timos normais. Os timomas malignos (três) e um timo normal não apresentaram células mióides. CONCLUSÕES: As células mióides podem ser identificadas e quantificadas pelo método imuno-histoquímico com anticorpo antidesmina, porém não existe correlação entre a quantidade de células mióides e as variáveis demográficas, clínico-patológicas. Elas não foram identificadas no timoma fusocelular

Effects of a soy-based dietary supplement compared with low-dose hormone therapy on the urogenital system: a randomized, double-blind, controlled clinical trial

OBJECTIVE: This study aims to compare the effects of a soy-based dietary supplement, low-dose hormone therapy (HT), and placebo on the urogenital system in postmenopausal women.METHODS: In this double-blind, randomized, placebo-controlled trial, 60 healthy postmenopausal women aged 40 to 60 years (mean time since menopause, 4.1 y) were randomized into three groups: a soy dietary supplement group (90 mg of isoflavone), a low-dose HT group (1 mg of estradiol plus 0.5 mg of norethisterone), and a placebo group. Urinary, vaginal, and sexual complaints were evaluated using the urogenital subscale of the Menopause Rating Scale. Vaginal maturation value was calculated. Transvaginal sonography was performed to evaluate endometrial thickness. Genital bleeding pattern was assessed. Statistical analysis was performed using χ test, Fisher’s exact test, paired Student’s t test, Kruskal-Wallis test, Kruskal-Wallis nonparametric test, and analysis of variance. For intergroup comparisons, Kruskal-Wallis nonparametric test (followed by Mann-Whitney U test) was used.RESULTS: Vaginal dryness improved significantly in the soy and HT groups (P = 0.04). Urinary and sexual symptoms did not change with treatment in the three groups. After 16 weeks of treatment, there was a significant increase in maturation value only in the HT group (P < 0.01). Vaginal pH decreased only in this group (P < 0.01). There were no statistically significant differences in endometrial thickness between the three groups, and the adverse effects evaluated were similar.CONCLUSIONS: This study shows that a soy-based dietary supplement used for 16 weeks fails to exert estrogenic action on the urogenital tract but improves vaginal dryness.This study aims to compare the effects of a soy-based dietary supplement, low-dose hormone therapy (HT), and placebo on the urogenital system in postmenopausal women. Methods: In this double-blind, randomized, placebo-controlled trial, 60 healthy postmeno227741749FAPESP - FUNDAÇÃO DE AMPARO À PESQUISA DO ESTADO DE SÃO PAULO03/04464-

The use of mesenchymal stem cells in bladder augmentation

To compare integration of bladder acellular matrix (BAM) with the bladder when seeded with mesenchymal stem cells (MSC) and when MSC are injected intravenously (IV).MSCs were isolated from bone marrow of EPM-1 Wistar male rats. Female rats were distributed into: Group A-BAM augmentation; Group B-BAM augmentation and MSCs IV administered; Group C-BAM-MSC seeded augmentation. Animals were killed on postoperative days 7, 14 and 28. Morphological analyses were performed using hematoxylin and eosin and Masson's trichrome, in addition to immunohistochemical staining with alpha-SMA and neurofilament for assessment of tissue repair. RNAm expression of the SRY gene was used to mark MSCs in the rats killed on postoperative day 28.The muscle layer was best repaired in Groups B and C. No difference in the repair of the urothelium in the animals in any of the three groups was found. Group B presented the smallest inflammatory reaction and the best neural repair on postoperative day 28. None of the animals examined had MSCs in their bladder graft.The MSCs were able to improve repair of the muscle layer and when injected intravenously, they were noted to initiate the neuronal regeneration process.Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)Universidade Federal de São Paulo, Dept Surg, BR-04109120 São Paulo, BrazilUniversidade Federal de São Paulo, Dept Nephrol, São Paulo, BrazilUniversidade Federal de São Paulo, Dept Pathol, São Paulo, BrazilUniversidade Federal de São Paulo, Dept Math, São Paulo, BrazilUniversidade Federal de São Paulo, Dept Surg, BR-04109120 São Paulo, BrazilUniversidade Federal de São Paulo, Dept Nephrol, São Paulo, BrazilUniversidade Federal de São Paulo, Dept Pathol, São Paulo, BrazilUniversidade Federal de São Paulo, Dept Math, São Paulo, BrazilWeb of Scienc